Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: There is little evidence to support the use of antipsychotic polypharmacy, and there are concerns about safety and side effects. Nonetheless, it is commonly used in the treatment of long-term inpatients with schizophrenia. This study investigated the effects of switching from a combination of first- and second-generation antipsychotics (FGA and SGA) to monotherapy (FGA or SGA) on relapse rates and psychiatric symptomatology.
Methods: Institutionalized patients with chronic psychotic disorders using a combination of SGA and FGA (n = 136) participated in a randomized open-label trial. The SWITCH group discontinued either FGA or SGA, the STAY group continued combination treatment. Relapse and psychotic symptoms were measured at baseline and during follow-up at 3, 6, and 9 months. Psychiatric symptomatology was measured using the Brief Psychiatric Rating Scale (BPRS). Relapse was defined as (i) an increase in BPRS score of at least 2 points on any item, or (ii) an increase of at least 4 points in total BPRS score and an adjustment of antipsychotics.
Results: A logistic regression model, corrected for sex, showed that the probability of relapse was significantly lower in the SWITCH group: 0.29 (95% CI 0.13-0.62). The protective effect of switching to monotherapy was attributable to patients continuing clozapine as monotherapy. For patients who did not experience a relapse nor dropped out, BPRS total scores decreased significantly more in the SWITCH group (p = 0.0001).
Conclusion: Switching from a combination of FGA and SGA to monotherapy in long-term inpatients does not increase the relapse rate and may even reduce it.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.schres.2022.03.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antipsychotic Treatment Approaches in Schizophrenia Spectrum and Other Psychotic Disorders: Prescription Patterns in Eight Different Diagnostic Groups.
J Clin Psychopharmacol
September 2025
LVR Institute for Research and Education, Department of Research.
Background: The objective of this study was to characterize real-world prescription patterns of antipsychotic drugs in patients with various psychiatric disorders with psychotic features.
Method: We analyzed the discharge prescription plans of 59,962 cases with the main diagnoses schizophrenia, schizoaffective disorder, acute transient psychotic disorder, delusional disorder, psychotic bipolar disorder, psychotic depression, organic delusional disorder or substance-induced psychosis. We analyzed the overall use, pharmacological subgroups, the use of long-acting injectable (LAI) formulations, and the frequency of prescription of the singular antipsychotic drugs.
Long-acting antipsychotics and mortality in patients with schizophrenia receiving homecare case management.
Psychiatry Clin Neurosci
September 2025
Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan.
Aim: Long-acting injectable antipsychotics (LAIs) offer several advantages over oral antipsychotic medications for treating schizophrenia. However, whether the benefits of LAIs extend to patients receiving homecare case management (CM) remains unclear.
Methods: This cohort study used Taiwan's National Health Insurance Research Database, enrolling 19,680 nationwide patients with schizophrenia who began homecare CM between January 1, 2000, and December 31, 2019.
Schizophrenia, Antipsychotic Drugs, and Risk of Breast Cancer.
J Clin Psychiatry
June 2025
Department of Psychiatry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India; Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, India.
Breast cancer is the commonest form of cancer among women. Literature suggests that women with schizophrenia are less likely to be screened for breast cancer and that, among women with schizophrenia who develop breast cancer, mortality rates are higher. This article examines recent meta-analyses and recent observational studies on the risk of breast cancer in women with schizophrenia, especially in the context of treatment with first generation and second generation antipsychotic (FGA, SGA) drugs.
View Article and Find Full Text PDFShould we be Prescribing Fluphenazine Long-Acting Injectable Formulation?
Curr Psychiatry Rep
June 2025
Department of Psychiatry, University of Michigan, 4250 Plymouth Rd, Ann Arbor, MI, 48105, US.
Purpose Of Review: This review critically examines the clinical utility, efficacy, and tolerability of fluphenazine long-acting injectable (LAI) relative to contemporary alternatives. It further evaluates whether fluphenazine LAI confers substantive advantages over other available formulations for the management of schizophrenia, particularly in light of its long-standing use.
Recent Findings: The extant literature demonstrates that the tolerability and side effect profile of fluphenazine LAI are comparable to other FGA LAIs but likely less favorable than available second-generation antipsychotic (SGA) LAIs.
Rare loss-of-function variants in HECTD2 and AKAP11 confer risk of bipolar disorder.
Nat Genet
April 2025
deCODE genetics/Amgen, Reykjavik, Iceland.
Bipolar disorder is a highly heritable psychiatric disorder; genome-wide association studies of bipolar disorder have yielded over 60 risk loci harboring common variants. To harness the information contained in rare loss-of-function (LOF) variants, holding promise for informing on the underlying biology, we performed a variant burden analysis for bipolar disorder using gene-based aggregation of LOF variants in whole-genome sequencing data from Iceland (4,197 cases, more than 200,000 controls) and the UK Biobank (1,881 cases, 426,622 controls). We found that HECTD2 was associated with bipolar disorder and confirmed it using the Bipolar Exome dataset.
View Article and Find Full Text PDF